A Risk-Scoring Model for Severe Checkpoint Inhibitor-Related Pneumonitis: A Case

A Risk-Scoring Model for Severe Checkpoint Inhibitor-Related Pneumonitis: A Case–Control Study

Published:2023-04-25 Issue:5 Volume:43 Page:347-357
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Deng Haiyi,Deng Jiating,Lin Xinqing,Guan Wenhui,Lin Ziying,Qiu Yanli,Yang Yilin,Wu Jianhui,Qiu Guihuan,Sun Ni,Zhou Maolin,Deng Jiaxi,Xie Xiaohong,Xie Zhanhong,Liu Ming,Qin Yinyin,Zhou Yanbin,Zhou Chengzhi^ORCID

Funder

National Key R&D Program of China

State Key Laboratory of Respiratory Disease-The open project

Beijing Xisike Clinical Oncology Research Foundation

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-023-01267-6.pdf

Reference50 articles.

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

2. Khan M, Lin J, Liao G, et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97: e11936.

3. Tan PS, Aguiar P Jr, Haaland B, et al. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer—a systematic review and network meta-analysis of 3024 participants. Lung Cancer. 2018;115:84–8.

4. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375–91.

5. Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721–8.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The application of bronchoscopy in the assessment of immune checkpoint inhibitor-related pneumonitis severity and recurrence;Scientific Reports;2024-07-25

2. Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis;The Oncologist;2024-06-17

3. Effectiveness of Immunotherapy in Non-Small Cell Lung Cancer Patients with a Diagnosis of COPD: Is This a Hidden Prognosticator for Survival and a Risk Factor for Immune-Related Adverse Events?;Cancers;2024-03-22

4. International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease;Translational Lung Cancer Research;2023-08

5. Risk factors and clinical outcomes of immune checkpoint inhibitor-related pneumonitis in patients with advanced non-small cell lung cancer：A single center experience;2023-07-21